Niddk Program Announcements
- Funding Opportunities to Support Cancer Moonshot. New opportunities announced for research grants that align with the goals of the Cancer. Program Announcements.
- The following ongoing program announcements indicate areas of research interest that have been published in the NIH Guide for Grants and Contracts. Click on the PA.
Niddk Program
Filter by: Reset Career Level. Established Investigator. Junior Faculty. Post Graduate.
Doctoral/Medical Student. High School/Undergraduate Student Activity Code. Centers - P20, P30, etc.
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: ANCILLARY STUDIES TO MAJOR ONGOING NIDDK CLINICAL RESEARCH STUDIES PAR-04-078.
Research Project - R01, P01, etc. Small Business - R41, R42, R43, R44, etc. Training and Career Development - F, K, T, and Loan Repayment, etc. Disease.
Diabetes. Digestive Diseases. Endocrine Diseases and Metabolic Diseases.
Hematologic Diseases. Kidney Disease.
Liver Disease. Nutrition. Obesity. Pancreatic Disease. Urologic Disease Announcement Type. Lav 150 commando for sale.
PA. PAR. PAS.
RFA Funding Opportunity Results.
NIH Announcements. The NIH Common Fund has recently issued two new Funding Opportunity Announcements (FOAs). These funding opportunities will focus on the following topics:. RFA-RM-17-025. RFA-RM-17-027 The aims of HuBMAP are to develop a framework for functional mapping the human body with cellular resolution to enhance our understanding of cellular organization-function.
Nih Niddk Program
HuBMAP will accelerate the development of the next generation of tools and techniques to generate 3D tissue maps using validated high-content, high-throughput imaging and omics assays, and establish an open data platform for integrating, visualizing data to build multi-dimensional maps. HuBMAP also intends to build partnerships with other funding agencies, programs, and the biomedical research community. The NIDDK requests applications to join a new research consortium “ (MPS-MOD)”. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK’s advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery.
In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing. Eventually, collections of iPSCs that capture the heterogeneity of T2D could be used to conduct “clinical trials in a dish”, to discover biomarkers of response and to develop personalized treatments. Letter of Intent due: February 20, 2018. Appication Due: March 20, 2018. The NIDDK Catalyst Award in Diabetes, Endocrinology & Metabolic Diseases. The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK’s traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas.
Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research must reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere. Application deadline: February 2, 2018. Application instructions and additional details provided in. The NIH Common Fund Metabolomics Program recently issued four new Funding Opportunity Announcements (FOAs) for the program’s second stage of funding. These funding opportunities will focus on the following topics:. The continued development of a robust National Metabolomics Data Repository to store, and make publicly available, raw and processed metabolomic data generated by NIH-funded research.